{
  "abstract": "Tissue factor (TF) protein is involved in activating the extrinsic blood coagulation cascade. TF expression is normally anatomically limited to the perivascular space, but TF is overexpressed in many malignancies, including pancreatic, cervical, prostate, and head and neck cancers, which makes TF an ideal antibody–drug conjugate (ADC) target. The TF-ADC tisotumab vedotin is approved for cervical cancer treatment but induces substantial side effects including ocular toxicities, peripheral neuropathy, and bleeding, limiting its further clinical development and warranting optimized ADC design to improve the therapeutic window. ADCE-T02 is a novel TF-ADC comprising the monoclonal antibody Ab-T02 conjugated via a self-immolative linker to the topoisomerase 1 inhibitor exatecan at an average drug-to-antibody ratio of 4.5. In contrast to tisotumab, Ab-T02 does not inhibit coagulation factor X activation. ADCE-T02 binds TF with high affinity inducing ADC internalization, exatecan release, cancer cell death, and bystander cytotoxicity in vitro. In vivo, ADCE-T02 is highly efficacious across a range of cell line–derived and patient-derived xenograft models including hard-to-treat models with large tumors, resistance to standard of care, low and/or heterogeneous expression of TF, and multidrug resistance. Importantly, ADCE-T02 demonstrates favorable pharmacokinetic properties and is well tolerated in nonhuman primates and in contrast to tisotumab vedotin and other auristatin-based ADCs shows no evidence of ocular, skin, and lung toxicities; peripheral nerve damage; or bleeding. In summary, ADCE-T02 constitutes a novel TF-ADC with a much improved preclinical therapeutic window. Phase I clinical development of ADCE-T02 in patients with advanced solid tumors is ongoing (ClinicalTrials ID: NCT06597721).",
  "abstract_shown": true,
  "affiliations": [
    "Adcendo Aps, Frederiksberg, Denmark.",
    "Multitude Therapeutics, Shanghai, China.",
    "Multitude Therapeutics, Redwood City, California."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 16,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Thomas T. Poulsen",
      "orcid": "0009-0002-6996-7562"
    },
    {
      "affs": [
        0
      ],
      "name": "Olga Ilina",
      "orcid": "0009-0009-2921-3863"
    },
    {
      "affs": [
        0
      ],
      "name": "Jonathan H. Wardman",
      "orcid": "0000-0001-7277-3801"
    },
    {
      "affs": [
        0
      ],
      "name": "Anne Bie",
      "orcid": "0009-0003-8198-4549"
    },
    {
      "affs": [
        0
      ],
      "name": "Jette Bornholdt",
      "orcid": "0000-0002-3494-6721"
    },
    {
      "affs": [
        0
      ],
      "name": "Mette Gillberg",
      "orcid": "0009-0008-3508-559X"
    },
    {
      "affs": [
        0
      ],
      "name": "Daniela Pontieri",
      "orcid": "0000-0001-7756-5331"
    },
    {
      "affs": [
        0
      ],
      "name": "Pernille Barkholt",
      "orcid": "0000-0002-3603-2915"
    },
    {
      "affs": [
        0
      ],
      "name": "Christophe Côme",
      "orcid": "0000-0001-5229-4440"
    },
    {
      "affs": [
        1
      ],
      "name": "Yue Zhang",
      "orcid": "0000-0001-9716-2927"
    },
    {
      "affs": [
        1
      ],
      "name": "Jianjian Zhang",
      "orcid": "0000-0001-5372-0499"
    },
    {
      "affs": [
        1
      ],
      "name": "Yixuan Wang",
      "orcid": "0009-0006-9945-7618"
    },
    {
      "affs": [
        1
      ],
      "name": "Huiyan Shi",
      "orcid": "0009-0009-1892-8468"
    },
    {
      "affs": [
        2
      ],
      "name": "Shu-Hui Liu",
      "orcid": "0000-0002-5221-6853"
    },
    {
      "affs": [
        1
      ],
      "name": "Xun Meng",
      "orcid": "0000-0001-9590-6670"
    },
    {
      "affs": [
        0
      ],
      "name": "Dominik Mumberg",
      "orcid": "0000-0002-6670-1497"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4gzvjrtd38n18.bib",
  "cited_by": 1,
  "doi": "10.1158/1535-7163.mct-26-0045",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13728795/",
  "id": "4gzvjrtd38n18",
  "issns": [
    "1535-7163",
    "1538-8514"
  ],
  "landing_url": "https://doi.org/10.1158/1535-7163.mct-26-0045",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Antibody-Drug Conjugates"
    ],
    [
      "heading",
      "Biological Agents & Therapies"
    ],
    [
      "heading",
      "Drug Resistance"
    ],
    [
      "heading",
      "First Disclosures"
    ],
    [
      "heading",
      "Preclinical Models"
    ],
    [
      "heading",
      "Reversal of Drug Resistance"
    ],
    [
      "heading",
      "Xenograft Models"
    ],
    [
      "openalex",
      "2403|Monoclonal and Polyclonal Antibodies Research"
    ]
  ],
  "openalex": "W7154688504",
  "pdf_url": "https://aacrjournals.org/mct/article-pdf/doi/10.1158/1535-7163.MCT-26-0045/3774773/mct-26-0045.pdf",
  "pmcid": "PMC13728795",
  "pmid": "41996633",
  "published": "2026-05-25",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/4gzvjrtd38n18.ris",
  "sources": [
    {
      "first_seen": "2026-11-07T12:21:42Z",
      "native_id": "PMC13728795",
      "source": "pmc",
      "url": "https://doi.org/10.1158/1535-7163.mct-26-0045"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2403|Monoclonal and Polyclonal Antibodies Research",
      "subfield": "immunology"
    }
  ],
  "title": "ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability",
  "title_text": "ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability",
  "type": "peer-reviewed",
  "updated_at": "2026-11-07T12:21:42Z",
  "url": "https://research.draconitic.com/paper/4gzvjrtd38n18",
  "venue": "Molecular Cancer Therapeutics",
  "versions": []
}